Tacrolimus

證據等級: L5

預測適應症: 3 個

Tacrolimus: From Atopic Dermatitis to Seborrheic Dermatitis

One-Sentence Summary

Tacrolimus is a calcineurin inhibitor internationally approved as a topical treatment for atopic dermatitis (and systemically for organ transplant rejection prophylaxis). The TxGNN model predicts it may also be effective for Seborrheic Dermatitis, with 2 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not registered in South Africa; internationally approved for atopic dermatitis (topical ointment) and organ transplant rejection prophylaxis (systemic)
Predicted New Indication	Seborrheic Dermatitis
TxGNN Prediction Score	99.26%
Evidence Level	L1
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, tacrolimus is a calcineurin inhibitor: it blocks calcineurin-dependent dephosphorylation of NF-AT, suppressing T-cell activation and downstream pro-inflammatory cytokine release. In its topical (ointment) form, this action underlies its established efficacy in atopic dermatitis, a T-cell-mediated inflammatory skin disease.

Seborrheic dermatitis shares an inflammatory, T-cell-associated component with atopic dermatitis, and both conditions are commonly managed with topical anti-inflammatory agents on sensitive facial skin. Because topical tacrolimus does not cause skin atrophy — a key limitation of long-term corticosteroid use — it is pharmacologically attractive for chronic, relapsing facial dermatoses that require maintenance therapy.

This mechanistic plausibility is directly supported by real-world use: topical calcineurin inhibitors (tacrolimus and pimecrolimus) have already been studied and used off-label in seborrheic dermatitis for over two decades, including dedicated Phase 3/4 maintenance trials, reinforcing that the TxGNN prediction reflects an area of active, mechanistically coherent clinical practice rather than a purely computational extrapolation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02004860	Phase 3	Completed	120	Evaluated tacrolimus ointment (Protopic) for maintenance treatment of severe facial seborrheic dermatitis in adults, aiming to reduce relapse frequency and steroid use
NCT01591070	Phase 4	Completed	104	Assessed whether proactive once/twice-weekly 0.1% tacrolimus ointment maintains remission and reduces exacerbation in adult facial seborrheic dermatitis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33010323	2021	RCT	J Am Acad Dermatol	Multicenter double-blind RCT: tacrolimus 0.1% vs ciclopiroxolamine 1% for maintenance therapy in severe facial seborrheic dermatitis
26512166	2015	Clinical Study	Annals of Dermatology	Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment, extending the atopic dermatitis intermittent-TCI regimen model
24171300	2013	RCT	Annals of Parasitology	Comparative trial of sertaconazole 2% cream vs tacrolimus 0.03% cream in 60 seborrheic dermatitis patients
12833030	2003	Open-label pilot	J Am Acad Dermatol	18 patients treated with 0.1% tacrolimus for up to 28 days; 61% achieved complete clearance
37067129	2023	Comparative study	Indian J Dermatol Venereol Leprol	Oral itraconazole + topical tacrolimus vs topical tacrolimus alone for maintenance treatment in Vietnam
39219446	2024	Cochrane SR/Network Meta-Analysis	Clin Exp Allergy	Network meta-analysis of topical anti-inflammatory treatments (including calcineurin inhibitors) for eczema-spectrum disease
19222250	2009	Review	Am J Clin Dermatol	Reviews pathophysiology, safety, and efficacy of topical calcineurin inhibitors specifically in seborrheic dermatitis
27804089	2017	Systematic Review	Am J Clin Dermatol	Systematic review of topical treatments (antifungals, keratolytics, corticosteroids, TCIs) for facial seborrheic dermatitis
19213227	2009	Review	J Drugs Dermatol	Overview of facial seborrheic dermatitis pathogenesis and emerging therapeutic options including TCIs
28685715	2017	Mechanistic/Cohort	Chinese Medical Journal	Investigates Staphylococcus epidermidis colonization and skin barrier impairment in facial seborrheic dermatitis, informing disease mechanism

South Africa Market Information

Tacrolimus is currently not registered with SAHPRA — no marketed products, dosage forms, or approved indication text are available in this evidence pack (0 licenses recorded). As a result, no formulation-specific South African labeling data (e.g., topical ointment strength, EML status) can be reported at this time.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase 3/4 trials plus a substantial, consistent literature base (including a randomized maintenance-therapy trial) support tacrolimus’s efficacy in facial seborrheic dermatitis, and the mechanistic rationale (calcineurin inhibition, low atrophy risk) is well established from its approved atopic dermatitis use. However, tacrolimus is not currently registered in South Africa and drug-level safety/label data are unavailable, so clinical adoption cannot proceed without further regulatory and safety input.

To proceed, the following is needed:

SAHPRA/TFDA-approved Professional Information (warnings, contraindications) — currently a blocking data gap (DG001)
Confirmed mechanism of action documentation from DrugBank (DG002)
A regulatory pathway assessment for South African registration, since tacrolimus is not currently marketed locally
Formal drug interaction (DDI) review, as none is currently on record
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.